Fig. 1From: Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learnedTumor-associated antigen (TAA) expression of approved ADCs across different indications; a expression of normal and tumoral tissue expressed in transcript per million (TPM) (GEPIA2), b effect on cell viability by CRISPR silencing in different cell lines (DepMap)Back to article page